Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

767.34
+2.630.34%
Volume:695.15K
Turnover:531.60M
Market Cap:726.25B
PE:50.18
High:770.68
Open:760.11
Low:756.34
Close:764.71
52wk High:939.86
52wk Low:623.78
Shares:946.46M
Float Shares:945.00M
Volume Ratio:2.94
T/O Rate:0.07%
Dividend:5.80
Dividend Rate:0.76%
EPS(TTM):15.29
EPS(LYR):11.76
ROE:86.29%
ROA:16.55%
PB:39.74
PE(LYR):65.26

Loading ...

Eli Lilly's New Diabetes Drug Shows Better Blood Sugar, Weight Loss Results Than Rival

Dow Jones
·
Just now

Bernstein Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

TIPRANKS
·
58 mins ago

Eli Lilly reports ‘positive’ results from ACHIEVE-3 Phase 3 trial

TIPRANKS
·
58 mins ago

Lilly's Oral Glp-1, Orforglipron, Superior to Oral Semaglutide in Head-to-Head Trial

THOMSON REUTERS
·
1 hour ago

Wisp: Expansion of Weight Care Vertical, Delivering Name-Brand Glp-1S Directly to Over 1.5 Mln Patients

THOMSON REUTERS
·
1 hour ago

Wisp: Patients Can Access Weight Loss Treatments With Savings up to 50%, No Insurance Required

THOMSON REUTERS
·
1 hour ago

Eli Lilly: Overall Safety & Tolerability Profile of Orforglipron in Achieve-3 Consistent With Previous Trials

THOMSON REUTERS
·
1 hour ago

Eli Lilly: Positive Topline Results From Achieve-3 Evaluating Safety & Efficacy of Orforglipron VS Oral Semaglutide

THOMSON REUTERS
·
1 hour ago

Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss?

Benzinga
·
1 hour ago

Eli Lilly: Orforglipron Met Primary, All Key Secondary Endpoints Across Each Dose Comparison VS Oral Semaglutide

THOMSON REUTERS
·
1 hour ago

Eli Lilly: for Primary Endpoint, Orforglipron Lowered a1c by 2.2% VS 1.4% With Oral Semaglutide at Highest Doses

THOMSON REUTERS
·
1 hour ago

Wisp: Priced Ozempic, Wegovy, Mounjaro at $598, $558, $489 per Month, Respectively, Inclusive of Consultation, Monthly Follow-Ups, Doorstep Delivery

THOMSON REUTERS
·
1 hour ago

Eli Lilly & Co: Promising Future Backed by Strong Pipeline and Positive Study Results

TIPRANKS
·
2 hours ago

Citi Remains a Buy on Eli Lilly & Co (LLY)

TIPRANKS
·
3 hours ago

Eli Lilly Cut to Hold From Buy by Berenberg

Dow Jones
·
3 hours ago

Eli Lilly Bets on Consumer-Oriented Strategy, Expects Weight Loss Drug Breakthrough in US Market

Deep News
·
3 hours ago

Drugmakers pledge to spend over $350B in U.S., WSJ reports

TIPRANKS
·
3 hours ago

Novo Nordisk Products and Portfolio Strategy Chief Helfgott: Sees Very Compelling Offer for Wegovy Pill Above Competitor Eli Lilly's Obesity Pill

THOMSON REUTERS
·
4 hours ago

Eli Lilly Says Phase 3 Study of Orforglipron Meets Primary Endpoint

MT Newswires Live
·
4 hours ago

Eli Lilly downgraded to Hold from Buy at Berenberg

TIPRANKS
·
5 hours ago